FDA approves Regeneron (REGN) Evkeeza - Reuters
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
FDA approves Regeneron (NASDAQ: REGN) Evkeeza - Reuters
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Analysis: Countries seek more Moderna, Pfizer/BioNTech COVID-19 shots as concerns mount over rival vaccines
- Lilly (LLY) requests revocation of EUA for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
- Regeneron (REGN) ReportsPhase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV